Business
Aeterna Zentaris to Present Poster on Novel Oral Anticancer Erk Inhibitors at Upcoming American Chemical Society's National Meeting
QUÉBEC CITY, Aug. 23, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:
...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Aug. 23, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that its Senior\n Director Medicinal Chemistry, Matthias Gerlach Ph.D., will present a\n poster on novel orally active anticancer Erk inhibitors, at the\n upcoming 242nd American Chemical Society's National Meeting to be held August 28\n through September 1, 2011 at the Colorado Convention Center in Denver,\n Colorado.\n\n\nThe poster #17068 titled, \"Novel Pyrido[2,3-b]pyrazines as orally active ERK inhibitors\", M. Gerlach, I. Seipelt, G. Mueller, T. Schuster, L. Blumenstein, B.\n Aicher, E. Guenther and M. Teifel, will be presented during the two\n following sessions:\n\n\n\n\n\nDate and time:\nPoster Session ID:\nVenue:\n\n\nMonday, August 29, 2011, 8 p.m. - 10 p.m. (Mountain Time)\nSci-Mix (Division of Medicinal Chemistry)\nHall D, Colorado Convention Center\n\n\n \n\n\nDate and time:\nPoster Session ID:\nVenue:\n\n\nWednesday, August 31, 2011, 7 p.m. - 11 p.m. (Mountain Time)\nGeneral Poster session (Division of Medicinal Chemistry)\nFour Seasons Ballroom, Colorado Convention Center\n\n\nAbout Erk 1/2 Inhibitor Compounds\n\n\nExtracellular signal-regulated kinases (\"Erks\") act in the\n Ras-Raf-Mek-Erk signaling cascade and regulate various cellular\n processes such as cell growth, proliferation and survival in response\n to a variety of extracellular or intrinsically mutated upstream\n signals. Aeterna Zentaris has identified small molecular compounds that\n selectively inhibit Erk1/2, among them, AEZS-131, which has shown to\n significantly inhibit tumor growth in in vivo studies. Early development of the Erk inhibitor AEZS-131 is an integral\n part of Aeterna Zentaris' kinase research program comprising the\n investigation of different compounds for single Erk inhibition, single\n PI3K inhibition and dual Erk/PI3K kinase inhibition.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a late-stage oncology drug development company\n currently investigating potential treatments for various cancers\n including colorectal, multiple myeloma, endometrial, ovarian, prostate\n and bladder cancer. The Company's innovative approach of \"personalized\n medicine\" means tailoring treatments to a patient's specific condition\n and to unmet medical needs. Aetern...